In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Those in the jab trials, however, kept off between 10 and 25 per cent of their body weight over the same timeframe, depending ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

The price you pay for Wegovy (semaglutide) may depend on factors such as your dosage, whether you have health insurance coverage, and the pharmacy you use. Financial assistance may be available to ...